Abstract
Abstract Scrub typhus is a poorly studied, but life-threatening, disease caused by the bacterium Orientia tsutsugamushi (Ot). Humoral immunity in scrub typhus patients wanes as early as one-year post-infection; yet its underlying mechanisms remain unclear. The objective of this study is to delineate mechanisms underlying humoral immune dysregulation and B cell dysfunction during acute Ot infection. Using a lethal scrub typhus C57BL/6 murine model, we evaluated splenic GC responses by immunofluorescent staining. Splenic germinal centers (GL-7 +cells) were formed at D4, but were nearly absent at D8, accompanied by randomly scattered T cells. Both infection days had comparable numbers of GC B cells and T follicular helper (Tfh) cells, indicating that GC loss at D8 was less likely due to cell death, but rather dysregulation in GC formation. To confirm this hypothesis, we performed RNAseq analysis of purified B220 +B cells and revealed a set of differentially expressed genes associated with B cell adhesion (S1PR1, ICAM1, GPR183) and co-stimulation (CD40, ICOS-L, SLAMF1) at D8. Notably, the downregulation of S1PR2 (a GC-specific adhesion gene) was most evident at D8, correlating to disrupted GC formation. Furthermore, transcriptomic data revealed significant downregulation of 71% B cell activation genes on D8, suggesting attenuation of B cell activation. Additional studies with low- and high-virulence Ot strains and comparative flow cytometry revealed significant differences in both B cell subsets (plasmablasts, marginal zone B cells) and T cell subsets (Tfh and Tfr cells). This is the first study showing marked dysregulation of B cell responses during Ot infection, which helps understand the transient immunity associated with scrub typhus. Supported by grants from NIH (R01 AI132674, R21 AI156536, R21 AI153586, R01 EY028773, T32 AI007526), Department of Defense Threat Reduction Agency grant (HDTRA1-19-1-0043), UTMB IHII Data Acquisition (CIRWH&IHII Pilot/ Phase II Research grant) and UTMB Center for Biodefense and Emerging Infectious Diseases (Pilot grant)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.